Drug intelligence / Profile preview

D099

Development stage: Preclinical
Lead developer: ME Therapeutics
Modality: Small Molecules

Overview

D099 is a small molecule prodrug candidate under preclinical development by ME Therapeutics designed for the targeted treatment of cancer, specifically by modulating suppressive myeloid cell biology within the tumor microenvironment. It aims to inhibit the immunosuppressive functions of myeloid cells, potentially improving outcomes when used alone or in combination with checkpoint inhibitors for immuno-oncology applications. The precise molecular structure and mechanism are currently undisclosed.

Beyond the preview

Go deeper on D099.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on D099.

Explore the full profile